2 research outputs found
Mechanistic Insights of Drug Resistance in <em>Staphylococcus aureus</em> with Special Reference to Newer Antibiotics
Staphylococcus aureus is the most ubiquitous microorganism in both environment as well as animals and exists as commensal and pathogenic bacterium. In past few years it has been emerged as a superbug causing serious burden on healthcare system. This bacterium has been found to be the most resistant one toward most of the antibiotics due to its rapid structural and genetic modifications. This chapter will shed light on various types of molecular mechanisms responsible for resistance of Staphylococcus aureus showcasing how it has been emerged as a superbug. Moreover, the recent approaches which include exploring of different drug targets keeping in view the structural and functional behavior of the Staphylococcus aureus has also been discussed
Human IFN-Îł immunity to mycobacteria is governed by both IL-12 and IL-23
Hundreds of patients with autosomal recessive, complete IL-12p40 or IL-12RĂ1 deficiency have been diagnosed over the last 20 years. They typically suffer from invasive mycobacteriosis and, occasionally, from mucocutaneous candidiasis. Susceptibility to these infections is thought to be due to impairments of IL- 12âdependent IFN-? immunity and IL-23âdependent IL-17A/IL-17F immunity, respectively. We report here patients with autosomal recessive, complete IL- 12RĂ2 or IL-23R deficiency, lacking responses to IL-12 or IL- 23 only, all of whom, unexpectedly, display mycobacteriosis without candidiasis. We show that aĂ T, ?d T, B, NK, ILC1, and ILC2 cells from healthy donors preferentially produce IFN-? in response to IL-12, whereas NKT cells and MAIT cells preferentially produce IFN-? in response to IL-23. We also show that the development of IFN-?âproducing CD4+ T cells, including, in particular, mycobacterium-specific TH1* cells (CD45RA-CCR6+), is dependent on both IL-12 and IL-23. Last, we show that IL12RB1, IL12RB2, and IL23R have similar frequencies of deleterious variants in the general population. The comparative rarity of symptomatic patients with IL-12RĂ2 or IL-23R deficiency, relative to IL-12RĂ1 deficiency, is, therefore, due to lower clinical penetrance. There are fewer symptomatic IL-23Râ and IL-12RĂ2âdeficient than IL-12RĂ1âdeficient patients, not because these genetic disorders are rarer, but because the isolated absence of IL-12 or IL-23 is, in part, compensated by the other cytokine for the production of IFN-?, thereby providing some protection against mycobacteria. These experiments of nature show that human IL-12 and IL-23 are both required for optimal IFN-?âdependent immunity to mycobacteria, both individually and much more so cooperatively